Despite these limitations, current results further strengthen the value of combinatorial GLP-1/GIP treatments as these approaches could not only increase efficacy in treating obesity and diabetes, but they could also increase patient retention and potentially improve the therapeutic index of GLP-1R agonists. This evidence concerns the gene GLP1R and obesity disorder.